Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study hypothesis is that metronomic treatment is more efficient than standard treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Pierre Fabre Laboratories
• Treatments: Capecitabine; Vinblastine; Vinorelbine

Criteria

Inclusion Criteria:

• Locally advanced or metastatic Human Epidermal Growth Factor Receptor2-Negative breast cancer

• WHO performance status < 3

Exclusion Criteria:

• Former treatment with Capecitabine or Vinorelbine

• Patients who have received more than one line of chemotherapy for metastatic disease

• Brain metastases

• Malabsorption syndrome

• Abnormal organ function

• pregnant or lactating women